PetMeds Receives Lowered $3 Takeover Bid From SilverCape
SilverCape Investments has cut its acquisition offer for PetMed Express to $3 per share, down from a prior $4 bid made in December 2025.
PetMed Express, the Nasdaq-listed online pet pharmacy known by its ticker PETS, confirmed Monday that its board has received a second unsolicited takeover proposal from SilverCape Investments Limited — this time at $3.00 per share in cash, a meaningful step down from the $4.00 per share offer SilverCape submitted back in December 2025. Both proposals have been described as non-binding and conditional, meaning neither carries a firm commitment to close a deal.
The reduction in offer price is a striking signal about how SilverCape views the company's trajectory. When an acquirer returns with a lower bid rather than walking away entirely, it typically indicates continued strategic interest tempered by deteriorating financial performance or shifting market conditions at the target. PetMeds has faced sustained headwinds in the competitive online pet health space, and the 25 percent drop in the proposed purchase price suggests SilverCape believes its leverage has grown in the intervening months.
Read more Retail Investors Abandon Magnificent Seven at Four-Year Low →
For shareholders, the situation presents a complicated calculus. A $3.00 per share cash offer may represent a premium depending on where PETS shares are trading, but the unsolicited and conditional nature of the bid means the board retains full discretion to reject, engage, or solicit competing offers. Boards in these circumstances often form special committees to evaluate proposals independently of management, and the company has not disclosed any response or next steps beyond confirming receipt.
The broader context matters here: the pet care sector saw explosive growth during the pandemic era, drawing in both established players and private investors, but normalization of consumer spending has squeezed margins across the industry. A lowered acquisition bid from a potential buyer reflects that sobering reset. Investors and analysts will be watching closely for any board statement indicating whether PetMeds intends to open a formal sale process or rebuff SilverCape's advances altogether.
Continue reading at GlobalNewswire.
